Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11930.0
(-0.33%)
KRW 11930.0
(-0.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -44.73 Billion KRW | -22.47% |
| 2022 | -36.52 Billion KRW | 41.4% |
| 2021 | -62.33 Billion KRW | -83.96% |
| 2020 | -33.88 Billion KRW | -106.35% |
| 2019 | -16.42 Billion KRW | 57.36% |
| 2018 | -38.51 Billion KRW | 3.54% |
| 2017 | -39.92 Billion KRW | 30.89% |
| 2016 | -57.77 Billion KRW | -18.85% |
| 2015 | -48.6 Billion KRW | -31.21% |
| 2014 | -37.04 Billion KRW | 17.71% |
| 2013 | -45.01 Billion KRW | 11.42% |
| 2012 | -50.82 Billion KRW | -49.52% |
| 2011 | -33.99 Billion KRW | -79.13% |
| 2010 | -18.97 Billion KRW | 39.21% |
| 2009 | -31.21 Billion KRW | -76.39% |
| 2008 | -17.69 Billion KRW | 12.64% |
| 2007 | -20.25 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -44.56 Billion KRW | 8.86% |
| 2024 Q1 | -48.89 Billion KRW | -9.3% |
| 2023 FY | -44.73 Billion KRW | -22.47% |
| 2023 Q4 | -44.73 Billion KRW | 14.84% |
| 2023 Q3 | -52.52 Billion KRW | 13.32% |
| 2023 Q2 | -60.6 Billion KRW | -50.62% |
| 2023 Q1 | -40.23 Billion KRW | -10.16% |
| 2022 Q3 | -40.79 Billion KRW | -4.08% |
| 2022 Q2 | -39.19 Billion KRW | 28.96% |
| 2022 FY | -36.52 Billion KRW | 41.4% |
| 2022 Q4 | -36.52 Billion KRW | 10.46% |
| 2022 Q1 | -55.17 Billion KRW | 11.49% |
| 2021 Q3 | -39.37 Billion KRW | -2.44% |
| 2021 FY | -62.33 Billion KRW | -83.96% |
| 2021 Q1 | -40.16 Billion KRW | -18.53% |
| 2021 Q2 | -38.44 Billion KRW | 4.29% |
| 2021 Q4 | -62.33 Billion KRW | -58.3% |
| 2020 FY | -33.88 Billion KRW | -106.35% |
| 2020 Q1 | -16.81 Billion KRW | -2.41% |
| 2020 Q2 | -32.31 Billion KRW | -92.18% |
| 2020 Q3 | -46.16 Billion KRW | -42.83% |
| 2020 Q4 | -33.88 Billion KRW | 26.6% |
| 2019 Q1 | -44.27 Billion KRW | -14.95% |
| 2019 FY | -16.42 Billion KRW | 57.36% |
| 2019 Q4 | -16.42 Billion KRW | 37.15% |
| 2019 Q3 | -26.12 Billion KRW | 32.55% |
| 2019 Q2 | -38.73 Billion KRW | 12.51% |
| 2018 Q2 | -35.78 Billion KRW | 22.19% |
| 2018 FY | -38.51 Billion KRW | 3.54% |
| 2018 Q4 | -38.51 Billion KRW | -31.73% |
| 2018 Q3 | -29.23 Billion KRW | 18.3% |
| 2018 Q1 | -45.98 Billion KRW | -15.18% |
| 2017 FY | -39.92 Billion KRW | 30.89% |
| 2017 Q3 | -47.36 Billion KRW | 11.44% |
| 2017 Q4 | -39.92 Billion KRW | 15.7% |
| 2017 Q1 | -55.53 Billion KRW | 3.86% |
| 2017 Q2 | -53.48 Billion KRW | 3.7% |
| 2016 Q1 | -64.24 Billion KRW | -32.16% |
| 2016 Q3 | -63.46 Billion KRW | -6.27% |
| 2016 Q4 | -57.77 Billion KRW | 8.97% |
| 2016 FY | -57.77 Billion KRW | -18.85% |
| 2016 Q2 | -59.71 Billion KRW | 7.04% |
| 2015 Q4 | -48.6 Billion KRW | -19.74% |
| 2015 Q1 | -53.91 Billion KRW | -45.53% |
| 2015 Q3 | -40.59 Billion KRW | 6.69% |
| 2015 Q2 | -43.5 Billion KRW | 19.31% |
| 2015 FY | -48.6 Billion KRW | -31.21% |
| 2014 Q4 | -37.04 Billion KRW | -4.84% |
| 2014 FY | -37.04 Billion KRW | 17.71% |
| 2014 Q3 | -35.33 Billion KRW | -15.55% |
| 2014 Q2 | -30.57 Billion KRW | 26.46% |
| 2014 Q1 | -41.58 Billion KRW | 7.63% |
| 2013 Q4 | -45.01 Billion KRW | -15.61% |
| 2013 FY | -45.01 Billion KRW | 11.42% |
| 2013 Q1 | -42.79 Billion KRW | 15.8% |
| 2013 Q2 | -33.82 Billion KRW | 20.97% |
| 2013 Q3 | -38.94 Billion KRW | -15.14% |
| 2012 Q1 | -41.27 Billion KRW | -21.43% |
| 2012 Q4 | -50.82 Billion KRW | -21.65% |
| 2012 Q2 | -43.01 Billion KRW | -4.23% |
| 2012 FY | -50.82 Billion KRW | -49.52% |
| 2012 Q3 | -41.77 Billion KRW | 2.89% |
| 2011 Q2 | -19.08 Billion KRW | 9.08% |
| 2011 Q1 | -20.99 Billion KRW | -10.63% |
| 2011 Q3 | -26.46 Billion KRW | -38.68% |
| 2011 FY | -33.99 Billion KRW | -79.13% |
| 2011 Q4 | -33.99 Billion KRW | -28.42% |
| 2010 Q3 | -19.96 Billion KRW | -12.6% |
| 2010 Q2 | -17.72 Billion KRW | 48.23% |
| 2010 Q4 | -18.97 Billion KRW | 4.93% |
| 2010 Q1 | -34.24 Billion KRW | -9.7% |
| 2010 FY | -18.97 Billion KRW | 39.21% |
| 2009 Q3 | -33.29 Billion KRW | -53.62% |
| 2009 FY | -31.21 Billion KRW | -76.39% |
| 2009 Q2 | -21.67 Billion KRW | -1.73% |
| 2009 Q1 | -21.3 Billion KRW | -20.39% |
| 2009 Q4 | -31.21 Billion KRW | 6.25% |
| 2008 Q2 | -12.45 Billion KRW | 45.29% |
| 2008 Q3 | -14.84 Billion KRW | -19.19% |
| 2008 Q4 | -17.69 Billion KRW | -19.18% |
| 2008 FY | -17.69 Billion KRW | 12.64% |
| 2008 Q1 | -22.76 Billion KRW | -12.4% |
| 2007 Q3 | -13.81 Billion KRW | 55.37% |
| 2007 Q4 | -20.25 Billion KRW | -46.65% |
| 2007 FY | -20.25 Billion KRW | 0.0% |
| 2007 Q1 | -29.25 Billion KRW | 0.0% |
| 2007 Q2 | -30.94 Billion KRW | -5.79% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 608.212% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 107.82% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 114.39% |
| HANDOK Inc. | 283.45 Billion KRW | 115.782% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 322.866% |
| Yuhan Corporation | -69.18 Billion KRW | 35.343% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 123.065% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | -1113.683% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 108.638% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | -37.932% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 159.114% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 221.437% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 154.21% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 278.164% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 608.212% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 72.014% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 122.262% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 126.169% |
| JW Holdings Corporation | 480.68 Billion KRW | 109.306% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 127.18% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | 38161.383% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 128.978% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 2002.511% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 294.484% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 125.566% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 186.069% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 608.212% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 128.26% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 112.489% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 128.978% |
| Yuhan Corporation | -69.18 Billion KRW | 35.343% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 132.895% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 174.964% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 110.424% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 128.978% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 138.485% |
| Korea United Pharm Inc. | 16.42 Billion KRW | 372.352% |
| CKD Bio Corp. | 143.29 Billion KRW | 131.218% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 138.542% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | -85.914% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 2002.511% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 110.579% |
| Boryung Corporation | 187.72 Billion KRW | 123.829% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 37.731% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 159.114% |
| JW Lifescience Corporation | 26.09 Billion KRW | 271.456% |